|
The PAI-cum-GMP (pre- approval inspection-cum-good manufacturing practices) inspection was closed with six observations.
There were no data integrity related observations and also, no repeat observations from the previous inspection.
There are 4 DMFs of this site under approval with the USFDA. The company said that it will closely work with the USFDA to address the observations.
Zydus Lifesciences is a discovery-driven, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies.
The company’s consolidated net profit surged 53.2% to Rs 800.7 crore on 9.1% increase in revenue from operations to Rs 4,368.8 crore in Q2 FY24 over Q2 FY23.
Shares of Zydus Lifesciences added 1.35% to end at Rs 679.95 on Friday, 22 December 2023.
The stock exchanges will remain closed on Monday, 25 December 2023, on the occasion of Christmas.
|